The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1608
ISSUE1608
October 5, 2020
Drugs for Migraine
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Migraine
October 5, 2020 (Issue: 1608)
An oral nonopioid analgesic is often sufficient for acute
treatment of mild to moderate migraine headache
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine headache pain in most...more
- American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019; 59:1.
- M Oskoui et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2019; 93:487.
- MJ Prior et al. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache 2010; 50:819.
- CC Suthisisang et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010; 50:808.
- C Suthisisang et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007; 41:1782.
- C Chen et al. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Headache 2015; 55:265.
- MM Johnston and AM Rapoport. Triptans for the management of migraine. Drugs 2010; 70:1505.
- Onzetra Xsail - sumatriptan nasal powder. Med Lett Drugs Ther 2016; 58:92.
- CJ Derry et al. Sumatriptan (all routes of administration) for acute migraine attacks in adults – overview of Cochrane reviews. Cochrane Database Syst Rev 2014; 5:CD009108.
- S Law et al. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev 2016; 4:CD008541.
- G Roberto et al. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Cephalalgia 2014; 34:5.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2020 September 10 (epub). Available at: http://secure.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- RG Wenzel et al. Serotonin syndrome risks when combining SSRI/SNRI drugs with triptans: is the FDA’s alert warranted? Ann Pharmacother 2008; 42:1692.
- Y Orlova et al. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 2018; 75:566.
- K Nezvalová-Henriksen et al. Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013; 28:759.
- US National Library of Medicine. Drugs and Lactation Data-base (LactMed). Available at: www.ncbi.nlm.nih.gov/books/NBK501922/. Accessed September 24, 2020.
- AD Hershey. CGRP – the next frontier for migraine. N Engl J Med 2017; 377:2190.
- Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine. Med Lett Drugs Ther 2020; 62:35.
- Rimegepant (Nurtec ODT) for acute treatment of migraine. Med Lett Drugs Ther 2020; 62:70.
- MJA Láinez et al. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007; 14:269.
- SD Silberstein et al. Dihydroergotamine (DHE) – then and now: a narrative review. Headache 2020; 60:40.
- MJ Marmura et al. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015; 55:3.
- RB Lipton et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 2010; 9:373.
- D Yarnitsky et al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache 2019; 59:1240.
- DE Chou et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial. Cephalalgia 2019; 39:3.
- C Tassorelli et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology 2018; 91:e364.
- JR Saper and AN Da Silva. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs 2013; 27:867.
- T Pringsheim et al. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008; 70:1555.
- EA MacGregor et al. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: results of a new analysis of data from five previously published studies. Gend Med 2010; 7:88.
- WM Mulleners et al. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia 2015; 35:51.
- H-C Diener et al. Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251:943.
- F Ashtari et al. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008; 118:301.
- S Silberstein et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009; 49:1153.
- H-C Diener et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27:814.
- SW Powers et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med 2017; 376:115.
- In brief: Warning against use of valproate for migraine prevention during pregnancy. Med Lett Drugs Ther 2013; 55:45.
- J Weston et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 2016; 11:CD010224.
- DW Dodick et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31:542.
- S Tarlaci. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol 2009; 32:254.
- WB Young et al. Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study. Headache 2013; 53:1430.
- Erenumab (Aimovig) for migraine prevention. Med Lett Drugs Ther 2018; 60:101.
- Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention. Med Lett Drugs Ther 2018; 60:177.
- Eptinezumab (Vyepti) for migraine prevention. Med Lett Drugs Ther 2020; 62:85.
- A Scheffler et al. Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 2020; 21:84.
- MD Ferrari et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019; 394:1030.
- WM Mulleners et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020; 19:814.
- JM Pavlovic et al. Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain 2020; 21:95.
- In brief: Erenumab (Aimovig) hypersensitivity. Med Lett Drugs Ther 2019; 61:48.
- Botulinum toxin for chronic migraine. Med Lett Drugs Ther 2011; 53:7.
- S Holland et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1346.
- BJ Gales et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother 2010; 44:360.
- LJ Stovner et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 2014; 34:523.
- JL Jackson et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10:e0130733.
- C Buettner et al. Simvastatin and vitamin D for migraine prevention: a randomized, controlled trial. Ann Neurol 2015; 78:970.
- A transcutaneous electrical nerve stimulation device (Cefaly) for migraine prevention. Med Lett Drugs Ther 2014; 56:78.
- AJ Starling et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018; 38:1038.
- H-C Diener et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 2019; 39:1475.
- X Ni et al. Acupuncture versus various control treatments in the treatment of migraine: a review of randomized controlled trials from the past 10 years. J Pain Res 2020; 13:2033.
- S-Q Fan et al. Efficacy of acupuncture for migraine prophylaxis: a trial sequential meta-analysis. J Neurol 2020 Aug 24 (epub).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Migraine
Article code: 1608a
Article code: 1608a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.